19 Results for "

Semaglutide

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "Semaglutide" in MCE Product Catalog:

45
Semaglutide
Semaglutide
0 Images
45 Publications Verification
Referencia número: HY-114118
No. CAS: 910463-68-2
Pureza:  99.84%
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
45
Semaglutide acetate
Semaglutide acetate
0 Images
45 Publications Verification
Referencia número: HY-114118B
No. CAS: 1997361-85-9
Pureza:  99.92%
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
45
Semaglutide TFA
Semaglutide TFA
0 Images
45 Publications Verification
Referencia número: HY-114118A
Pureza:  99.92%
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
Semaglutide (crude)
Semaglutide (crude)
0 Images
Referencia número: HY-114118CP
No. CAS: 910463-68-2
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
Semaglutide-13C6,15N TFA
Semaglutide-13C6,15N TFA
0 Images
Referencia número: HY-114118S3
Pureza:  96.04%
Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
Semaglutide Main Chain (9-37)
Semaglutide Main Chain (9-37)
0 Images
Referencia número: HY-Z11724
No. CAS: 1169630-82-3
Target:  

Drug Derivative

Áreas de investigación:  

Metabolic Disease

Semaglutide Main Chain (9-37) is a peptide starting material in the synthesis of semaglutide (HY-114118) .
loading...
    loading...
View All Sizes
Semaglutide-d8
Semaglutide-d8
0 Images
Referencia número: HY-114118S
Target:  

Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA
0 Images
Referencia número: HY-114118S1
Target:  

Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu
0 Images
Referencia número: HY-45894
No. CAS: 1118767-16-0
Synonyms: Semaglutide side chain
Target:  

GLP Receptor

Áreas de investigación:  

Metabolic Disease Inflammation/Immunology

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution .
loading...
    loading...
View All Sizes
NNC0165-1273 TFA
NNC0165-1273 TFA
0 Images
Referencia número: HY-P11291A
Target:  

Neuropeptide Y Receptor

Áreas de investigación:  

Metabolic Disease

NNC0165-1273 TFA is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 TFA blocks Ghrelin-induced cFos expression. NNC0165-1273 TFA reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 TFA reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 TFA can be used in studies related to diet-induced obesity .
loading...
    loading...
View All Sizes
TN-783
TN-783
0 Images
Referencia número: HY-179131
Target:  

NOD-like Receptor (NLR)

Áreas de investigación:  

Metabolic Disease Inflammation/Immunology

TN-783 is an orally active, brain-penetrant NLRP3 (IC50 = 19.3 nM) inhibitor. TN-783 enhances the effects of the GLP-1 receptor agonist semaglutide. TN-783 requires sustained targeted action, not permanent metabolic remodeling. TN-783 can be used for the study of obesity .
loading...
    loading...
View All Sizes
Berobenatide
Berobenatide
0 Images
Referencia número: HY-P11235
No. CAS: 3028974-74-2
Synonyms: PF-08653944; MET-097
Target:  

GLP Receptor

Áreas de investigación:  

Metabolic Disease

Berobenatide (PF-08653944; MET-097) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide induces weight loss in diet-induced obese mice. Berobenatide can be used in obesity-related research .
loading...
    loading...
View All Sizes
Semaglutide-FITC
Semaglutide-FITC
0 Images
Referencia número: HY-114118F4
Synonyms: Semaglutide-Lys(FITC)
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Fluorescent Dye Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease

Semaglutide-FITC (Semaglutide-Lys(FITC)) is a fluorescent tracer probe (Ex/Em = 495/520 nm) obtained by covalently coupling the green fluorescent dye fluorescein isothiocyanate (FITC) (HY-66019) to the long-acting analogue of GLP-1, Semaglutide (HY-114118). Semaglutide-FITC can be used for studies on Semaglutide receptor binding (GLP-1R), cell uptake and endocytosis, in vivo tissue distribution, and the targeting efficiency of delivery systems .
loading...
    loading...
View All Sizes
Semaglutide, Cy5 labeled
Semaglutide, Cy5 labeled
0 Images
Referencia número: HY-114118F5
Synonyms: Semaglutide-Cys(Cy5)
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Fluorescent Dye Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease

Semaglutide, Cy5-labeled (Semaglutide-Cys(Cy5)) is a CY5 (HY-D0821) -labeled version of Semaglutide (HY-114118) (Ex/Em = 633/670 nm). Semaglutide, Cy5-labeled can be used for studies on Semaglutide receptor binding (GLP-1R), cellular uptake and endocytosis, in vivo tissue distribution, and the targeting efficiency of delivery systems .
loading...
    loading...
View All Sizes
Semaglutide sodium
Semaglutide sodium
0 Images
Referencia número: HY-114118C
No. CAS: 2924330-56-1
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Áreas de investigación:  

Neurological Disease Metabolic Disease Cancer

Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
NNC0165-1273
NNC0165-1273
0 Images
Referencia número: HY-P11291
Target:  

Neuropeptide Y Receptor

Áreas de investigación:  

Metabolic Disease

NNC0165-1273 is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 blocks Ghrelin-induced cFos expression. NNC0165-1273 reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 can be used in studies related to diet-induced obesity .
loading...
    loading...
View All Sizes
Semaglutide Antibody
Semaglutide Antibody
0 Images
Referencia número: HY-P810528

Host:  

Rabbit

Application:  

WB, IHC-P, ELISA

Reactivity:  

Human

loading...
    loading...
View All Sizes
Berobenatide acetate
Berobenatide acetate
0 Images
Referencia número: HY-P11235A
Synonyms: PF-08653944 acetate; MET-097 acetate
Target:  

GLP Receptor

Áreas de investigación:  

Metabolic Disease

Berobenatide acetate (PF-08653944 acetate; MET-097 acetate) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide acetate induces weight loss in diet-induced obese mice. Berobenatide acetate can be used in obesity-related research .
loading...
    loading...
View All Sizes
NNC0165-1273 acetate
NNC0165-1273 acetate
0 Images
Referencia número: HY-P11291B
Target:  

Neuropeptide Y Receptor

Áreas de investigación:  

Metabolic Disease

NNC0165-1273 acetate is a selective NPY Y2 receptor agonist with a Ki of 2 nM and an EC50 of 5.0 nM. NNC0165-1273 acetate blocks Ghrelin-induced cFos expression. NNC0165-1273 acetate reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice. When used in combination with Semaglutide (HY-114118), NNC0165-1273 acetate reduces preference for high-fat diet, promotes body weight loss, and produces sustained weight loss effects in diet-induced obese rats. NNC0165-1273 acetate can be used in studies related to diet-induced obesity .
loading...
    loading...
View All Sizes
  • 1
Assay Types